Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03432884 · ClinicalTrials.gov registry record · Phase 1
A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03432884 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 40 participants.
The verdict
NCT03432884, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
A Two-Part Phase 1 Study to Investigate A) Safety and Tolerability of Supratherapeutic dose of Zanubrutinib (BGB-3111) and B) Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG BGB-3111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-01-25 |
| Est. Completion | 2018-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03432884
The ClinicalTrials.gov registry entry for NCT03432884 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03432884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03432884 about?
NCT03432884 is a clinical study titled "A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects". A Two-Part Phase 1 Study to Investigate A) Safety and Tolerability of Supratherapeutic dose of Zanubrutinib (BGB-3111) and B) Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
What is the current status of trial NCT03432884?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-01-25. Estimated completion is 2018-04-16.
What interventions are being tested in trial NCT03432884?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), BGB-3111 (DRUG).
Who is sponsoring clinical trial NCT03432884?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.